N4 Pharma Plc

AIM:N4P Stok Raporu

Piyasa değeri: UK£2.2m

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

N4 Pharma Yönetim

Yönetim kriter kontrolleri 3/4

N4 Pharma's CEO is Nigel Theobald, appointed in Jan 2014, has a tenure of 10.75 years. total yearly compensation is £82.50K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 4.3% of the company’s shares, worth £93.40K. The average tenure of the management team and the board of directors is 5.4 years and 5.4 years respectively.

Anahtar bilgiler

Nigel Theobald

İcra Kurulu Başkanı

UK£82.5k

Toplam tazminat

CEO maaş yüzdesi100.0%
CEO görev süresi10.8yrs
CEO sahipliği4.3%
Yönetim ortalama görev süresi5.4yrs
Yönetim Kurulu ortalama görev süresi5.4yrs

Son yönetim güncellemeleri

Recent updates

Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth

Oct 11
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation

Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?

Mar 18
Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?

Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay

Mar 01
Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay

Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth

Dec 07
Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth

CEO Tazminat Analizi

Nigel Theobald'un ücretlendirmesi N4 Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-UK£1m

Mar 31 2024n/an/a

-UK£1m

Dec 31 2023UK£83kUK£83k

-UK£1m

Sep 30 2023n/an/a

-UK£1m

Jun 30 2023n/an/a

-UK£925k

Mar 31 2023n/an/a

-UK£977k

Dec 31 2022UK£78kUK£78k

-UK£1m

Sep 30 2022n/an/a

-UK£1m

Jun 30 2022n/an/a

-UK£1m

Mar 31 2022n/an/a

-UK£1m

Dec 31 2021UK£75kUK£75k

-UK£2m

Sep 30 2021n/an/a

-UK£2m

Jun 30 2021n/an/a

-UK£2m

Mar 31 2021n/an/a

-UK£2m

Dec 31 2020UK£72kUK£72k

-UK£1m

Sep 30 2020n/an/a

-UK£1m

Jun 30 2020n/an/a

-UK£863k

Mar 31 2020n/an/a

-UK£869k

Dec 31 2019UK£70kUK£70k

-UK£876k

Sep 30 2019n/an/a

-UK£1m

Jun 30 2019n/an/a

-UK£1m

Mar 31 2019n/an/a

-UK£1m

Dec 31 2018UK£70kUK£70k

-UK£1m

Tazminat ve Piyasa: Nigel's total compensation ($USD109.56K) is below average for companies of similar size in the UK market ($USD366.33K).

Tazminat ve Kazançlar: Nigel's compensation has increased whilst the company is unprofitable.

CEO

Nigel Theobald (60 yo)

10.8yrs

Görev süresi

UK£82,500

Tazminat

Mr. Nigel James Theobald has been Chief Executive Officer of N4 Pharma Plc since May 3, 2017 and serves as its Executive Director. Mr. Theobald served as the Head of Emerge Marketing Ltd., for Alltracel Ph...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Nigel Theobald
Founder10.8yrsUK£82.50k4.3%
£ 93.4k
David Templeton
Executive Director & Technical Director5.4yrsUK£51.22kVeri yok
Luke Cairns
Executive Director4.3yrsUK£45.72k0.036%
£ 785.8
Rob Harris
Head of CMC Development4.7yrsVeri yokVeri yok
Andrew Leishman
Consultant5.8yrsVeri yokVeri yok

5.4yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: N4P's management team is seasoned and experienced (5.4 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Nigel Theobald
Founderno dataUK£82.50k4.3%
£ 93.4k
David Templeton
Executive Director & Technical Director7.4yrsUK£51.22kVeri yok
Luke Cairns
Executive Directorno dataUK£45.72k0.036%
£ 785.8
Michael Palfreyman
Independent Non-Executive Directorless than a yearVeri yokVeri yok
Christopher Britten
Independent Non-Executive Chairman5.4yrsUK£24.00kVeri yok

5.4yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: N4P's board of directors are considered experienced (5.4 years average tenure).